Stock Financial Ratios, Dividends, Split History

SRLP / Sprague Resources LP financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)542.05
Enterprise Value ($M)535.23
Book Value ($M)189.04
Book Value / Share8.32
Price / Book4.11
NCAV ($M)-373.73
NCAV / Share-16.44
Price / NCAV-1.33
Share Statistics
Common Shares Outstanding 22,727,284
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.22
Return on Assets (ROA)0.03
Return on Equity (ROE)0.24
Balance Sheet (mrq) ($M)
Quick Ratio0.81
Current Ratio1.32
Income Statement (mra) ($M)
Sales Revenue Net2,854,996,000.00
Operating Income64.22
Net Income29.50
Cash Flow Statement (mra) ($M)
Cash From Operations57.04
Cash from Investing-153.27
Cash from Financing57.04
Identifiers and Descriptors
Central Index Key (CIK)1525287

Split History

Stock splits are used by Sprague Resources LP to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

50 Energy Sector Top Yield Dividend Stocks For June

23h seekingalpha
Energy firms with over 5% dividend yield showed a refining & marketing firm tops on its list, CrossAmerica Partners, for upside and net gains, and Sanchez Midstream for yield. (10-0)

90 Champions, Contenders And Challengers Are Wall Street Dividend Stars For June

2018-06-12 seekingalpha
Champion dividend stocks sustain 25 or more annual dividend increases; Contenders show 10 to 24; Challengers have 5 to 9. WallStar selections all show .7% or higher price target upsides. (35-0)

Ferrellgas Partners (FGP) Lags Q3 Earnings, Sales Estimates

2018-06-07 zacks
Ferrellgas Partners LP (FGP - Free Report) reported third-quarter fiscal 2018 adjusted earnings of 18 cents per unit, missing the Zacks Consensus Estimate of 26 cents by 30.8%. Total Revenues In the reported quarter, Ferrellgas Partners’ total revenues were $515.8 million, missing the Zacks Consensus Estimate of $621 million by 17%. The top line also declined 4.1% from $538 million in the prior-year quarter. (17-0)

50 Energy Sector Top Yield And 50 Top Wall St. Target Dividend Stocks For May

2018-05-17 seekingalpha
Energy firms with at least 0.71 broker target upside and 2% dividend yield showed midstream firms high on lists led by Blueknight Energy for upside and Sandridge for yield. (34-0)

Sprague Resources' (SRLP) CEO David Glendon on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good day, ladies and gentlemen, and thank you for your patience. You've joined the Sprague Resources LP Q1 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference may be recorded. (1-0)

CUSIP: 849343108